Finally, treating CRC-088T PDXs (KRAS G12V; high-affinity ligand, 61.3%; low-affinity ligand, 38.7%) with GC1118 and cetuximab resulted in TGII values of 10.8% (p = 0.001) and 47.6% (p = 0.91), respectively (GC1118 vs. cetuximab, p = 0.012; Figure 3A, lower panel and Table S2). This evidence concerns the gene KRAS and colorectal carcinoma.